Revolution Medicines reported a survival advantage for its pan-RAS drug daraxonrasib in a global phase III study in metastatic pancreatic ductal adenocarcinoma. Patients treated with the daily pill lived a median of 13.2 months versus 6.7 months for those on standard chemotherapy, according to the trial update highlighted by STAT+. The readout is tied to RAS-solute targeting across RAS variants, with the company highlighting outcomes for key patient subsets as well as intent-to-treat analyses. The company indicated it plans to use the data to support an FDA approval application, framing the update as a potential shift for a disease with limited survival improvements from existing systemic therapies. For the oncology pipeline, the signal adds momentum to RAS-targeted strategies and raises expectations for how regulators and payers may evaluate clinical benefit magnitude in pancreatic cancer where late-stage disease and treatment resistance remain dominant challenges.